What is the role of stereotactic body radiotherapy (SBRT) in oligometastatic lung cancer?

References

1. [1]

   Mayinger M, Kotecha R, Sahgal A et al.. “Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines.” Lung cancer (Amsterdam, Netherlands) (2023). PMID: 37390723 ↗

   L1GUIDELINECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
2. [2]

   Iyengar P, All S, Berry MF et al.. “Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.” Practical radiation oncology (2023). PMID: 37294262 ↗

   L1GUIDELINECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
3. [3]

   Gooijer SA, Gazendam ASM, Torensma B et al.. “Metastasectomy versus stereotactic body radiotherapy for patients with oligometastatic colorectal lung metastases: a systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2025). PMID: 40300380 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
4. [4]

   Hasan N, Yazdanpanah O, Harris JP et al.. “Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review.” Critical reviews in oncology/hematology (2025). PMID: 40064250 ↗

   L5SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
5. [5]

   Jeong JU, Rim CH, Yoo GS et al.. “The Clinical Efficacy of Colorectal Cancer Patients with Pulmonary Oligometastases by Sterotactic Body Ablative Radiotherapy: A Meta-Analysis.” Cancer research and treatment (2023). PMID: 38097919 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
6. [6]

   Maury P, Sayous Y, Marnaoui R et al.. “Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 40714135 ↗

   L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
7. [7]

   Siva S, Sakyanun P, Mai T et al.. “Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37179526 ↗

   L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats
8. [8]

   Laeseke P, Ng C, Ferko N et al.. “Stereotactic body radiation therapy and thermal ablation for treatment of patients with pulmonary metastases: a systematic literature review and meta-analysis.” BMC pulmonary medicine (2025). PMID: 40269808 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
9. [9]

   Chierici A, Vinci D, Liddo G et al.. “Multimodal treatment improves survival in patients with lung metastases from colorectal cancer: A network meta-analysis.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2025). PMID: 39844651 ↗

   L2SR_OBSCited in: Bottom Line, Current Evidence and Standard, On the Horizon
10. [10]

    Kunkyab T, Hyde D, Mou B et al.. “Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2026). PMID: 41775003 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
11. [11]

    Li Q, Ma H, Zheng R et al.. “Durvalumab Combined With Chemotherapy and SABR Therapy in Patients With Oligometastatic Non-small Cell Lung Cancer: A Multicenter Phase 2 Study.” International journal of radiation oncology, biology, physics (2025). PMID: 41005623 ↗

    L4TRIAL_NONRANDOMCited in: Current Evidence and Standard, On the Horizon
12. [12]

    Filippi AR, Rulli E, Signorelli D et al.. “Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.” Clinical lung cancer (2025). PMID: 40781023 ↗

    L5TRIAL_NONRANDOMCited in: Current Evidence and Standard, On the Horizon
13. [13]

    Kim H, Venkatesulu BP, McMillan MT et al.. “Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials.” International journal of radiation oncology, biology, physics (2022). PMID: 35973624 ↗

    L2SR_OBSCited in: Applicability and Caveats
14. [14]

    Verma V, Yegya-Raman N, Sprave T et al.. “A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.” International journal of radiation oncology, biology, physics (2022). PMID: 35675852 ↗

    L2SR_OBSCited in: Applicability and Caveats
15. [15]

    Choi HS, Jeong BK, Kang KM et al.. “Tumor Control and Overall Survival after Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer: A Meta-Analysis.” Cancer research and treatment (2020). PMID: 32718145 ↗

    L2SR_OBSCited in: Applicability and Caveats
16. [16]

    Tsao MN, Ven LI', Cheung P et al.. “Stereotactic Body Radiation Therapy for Extracranial Oligometastatic Non-small-cell Lung Cancer: A Systematic Review.” Clinical lung cancer (2019). PMID: 31959533 ↗

    L2SR_OBSCited in: Applicability and Caveats